HCM
NERV icon

Highbridge Capital Management’s Minerva Neurosciences NERV Stock Holding History

Highbridge Capital Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,686
Closed -$138K – 1565
2016
Q2 		$138K Buy
+1,686
New +$107K ﹤0.01% 1288

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Highbridge Capital Management's NERV Position: Q3 2016 in Review

Highbridge Capital Management sold out of Minerva Neurosciences (NERV) in Q3 2016, closing a stake of 1,686 shares — an estimated $138K sold.

Highbridge Capital Management first reported a position in NERV in Q2 2016 and held it in 1 quarter. The position peaked at $138K in Q2 2016. 67 funds tracked by Wall St. Rank hold NERV as of Q3 2016.

  • Highbridge Capital Management reported no remaining Minerva Neurosciences position as of Q3 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 1,686 Minerva Neurosciences shares in Q3 2016, an estimated $138K.
  • Highbridge Capital Management first reported a position in Minerva Neurosciences in Q2 2016 and held it in 1 quarter.
  • Highbridge Capital Management's Minerva Neurosciences position peaked at $138K in Q2 2016.
  • 67 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2016.

Based on Highbridge Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.